Recent developments highlight Vericel's Q3 2026 financial results, operational updates including strong surgeon interest in MACI Arthro, and raised full-year financial guidance.

• Vericel reported Q3 2026 revenue of $85.4 million and net income of $14.2 million, with basic EPS of $0.28 and diluted EPS of $0.27 as of September 30, 2026 [S2].
• The company raised its full-year 2026 financial guidance following strong Q3 results [N2].
• Surgeon interest in the arthroscopic delivery of MACI (MACI Arthro) remains strong, with over 900 surgeons trained, contributing to increased MACI biopsies and implants [N1].
• Vericel's Q3 2026 earnings call and transcript provided detailed operational and financial insights [N1][N3].
• The company continues to focus on expanding MACI indications and geographic reach, including regulatory efforts in the UK [N1].

Vericel's recent FDA approvals and product innovations, such as the arthroscopic delivery of MACI, provide avenues for expanding its addressable market and surgeon adoption. The company's efforts to commercialize MACI in new geographies like the UK and expand indications to ankle cartilage repair could broaden revenue streams. Strong financial performance and liquidity support ongoing investments in growth initiatives and manufacturing capacity.

The company's reliance on a limited product portfolio focused on niche markets exposes it to risks from regulatory changes, reimbursement challenges, and competitive therapies. Manufacturing scale-up and supply chain dependencies, including reliance on third-party suppliers for key materials, could impact operations. Variability in burn incidence and seasonality in MACI sales may cause fluctuations in revenue and cash flow. Failure to achieve regulatory approvals or market acceptance in new indications or geographies could limit growth.

Vericel's moat is based on its proprietary autologous cell therapy products with FDA approvals, including MACI's differentiated arthroscopic delivery system and Epicel's unique status as the only FDA-approved cultured epidermal autograft for large burns. Long-term supply agreements and specialized manufacturing capabilities support product exclusivity. The company's clinical data and regulatory approvals create barriers to entry, while its focus on niche markets with unmet medical needs enhances competitive positioning.

• Regulatory and Approval Risks: Delays or failures in obtaining regulatory approvals for new indications or geographic expansions could impact product commercialization.
• Manufacturing and Supply Chain Risks: Dependence on third-party suppliers and the validation of new manufacturing facilities pose operational risks.
• Market Adoption and Reimbursement Risks: Limited adoption by surgeons or burn centers and challenges in insurance coverage could affect revenue growth.
• Revenue Variability: Seasonality in MACI sales and variability in burn incidence for Epicel contribute to fluctuations in financial results.

• Vericel Corporation is a leading provider of advanced therapies for sports medicine and severe burn care markets, with a portfolio of FDA-approved autologous cell therapy and specialty biologic products [S1].
• The company markets two FDA-approved autologous cell therapy products: MACI (for knee cartilage repair) and Epicel (for severe burns), and one FDA-approved specialty biologic product, NexoBrid (for eschar removal in burns) [S1].
• MACI is an autologous cellularized scaffold product indicated for repair of full-thickness cartilage defects of the knee, with an FDA-approved arthroscopic delivery method (MACI Arthro) launched commercially in Q3 2024 [S1].
• Epicel is a permanent skin replacement for patients with deep-dermal or full-thickness burns covering ≥30% total body surface area, designated as a Humanitarian Use Device but not price-restricted due to a 2016 FDA label update [S1].
• NexoBrid is a topically administered biological orphan product approved for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns, with FDA approval expanded in August 2024 [S1].
• Vericel operates a cell manufacturing facility in Cambridge, Massachusetts, and a leased facility in Burlington, Massachusetts, intended to become the primary manufacturing site for MACI and Epicel after validation [S1].
• NexoBrid manufacturing is conducted by MediWound in Israel, with some raw materials sourced from Taiwan [S1].
• The company has a long-term supply agreement with Matricel GmbH for collagen membranes used in MACI manufacturing, effective through 2030 with extension options [S1].
• The addressable market for MACI in the U.S. includes approximately 60,000 patients annually with larger cartilage lesions likely to secure insurance authorization; the company is pursuing regulatory approval to expand MACI use to the ankle and to commercialize MACI in the UK [S1].
• Epicel is underutilized relative to clinical need due to prior lack of promotional efforts; approximately 1,500 patients annually in the U.S. meet the labeled indication for Epicel [S1].
• MACI sales exhibit seasonality with stronger sales in Q4; Epicel revenues have inherent variability without significant seasonality [S1].
• The company reported Q3 2026 financial results with revenue of $85.4 million, net income of $14.2 million, basic EPS of $0.28, and diluted EPS of $0.27 as of September 30, 2026 [S2].
• Liquidity ratios as of 2026-09-30 include a current ratio of 5.13 and a cash ratio of 3.11, with cash and equivalents totaling approximately $133.5 million and short-term investments of $36.8 million [S2].
• Recent news highlights include Q3 2026 earnings call, financial results, raised full-year guidance, and strong surgeon interest in MACI Arthro technique [N1][N2][N3][N4].